Thymosin Alpha-1: Immune Signaling and Research Applications
Timozin α1: T-sejt és veleszületett immunitás vonatkozású kutatási összefoglaló; preklinikai és laboratóriumi keretek.
Background
Thymosin Alpha-1 (Tα1) is a 28-amino-acid acetylated peptide originally isolated from thymosin fraction 5 in the 1970s. It is produced endogenously as a cleavage product of prothymosin-α and has been investigated across five decades of immunology research. In various jurisdictions it is approved as a therapeutic for specific indications (notably as adjunct therapy for viral hepatitis in some regions); this article addresses research-grade use only.
Molecular profile
- Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn (28 aa)
- Molecular weight: ~3,108 Da
- Modifications: N-terminal acetylation (critical for bioactivity in published structure-activity studies)
- CAS: 62304-98-7
Mechanistic themes in literature
Research into Tα1's immunological activity has explored several intersecting pathways:
- Toll-like receptor signaling — Tα1 has been characterized as a TLR2 and TLR9 ligand in dendritic cells, promoting MyD88-dependent signaling and dendritic cell maturation
- Th1/Th2 balance — multiple studies report shifts toward Th1-type responses (IL-2, IFN-γ) with altered Th2 cytokine output
- T-cell maturation — influence on thymocyte differentiation and peripheral T-cell activation markers in immunocompromised models
- NK cell function — augmentation of natural killer cytotoxicity in cancer and infection models
- Dendritic cell cross-presentation — improved antigen presentation relevant to vaccine adjuvant research
- Regulatory T-cell modulation — context-dependent effects reported in autoimmunity and chronic infection models
What laboratories typically study
- In vitro immunology — PBMC cultures, cytokine release assays, TLR reporter lines, dendritic cell maturation markers
- Infection models — rodent models of viral and fungal infection measuring pathogen load, survival, and immune gene expression
- Vaccine adjuvancy — co-administration studies with model antigens evaluating antibody titers and cellular response
- Oncology research — combination studies in solid-tumor xenografts exploring immune-checkpoint pairings
- Structure-activity — N-terminal acetylation importance, truncated peptide analogs, species cross-reactivity
Handling and quality
- Supplied as lyophilized powder; typical research format 5 mg
- Store lyophilized at -20°C, light-protected
- Reconstitute with sterile/bacteriostatic water shortly before use
- Reconstituted solution stable ~4 weeks at 2–8°C
- Verify purity by HPLC (≥99.0%) with mass-spectrometric identity confirmation; obtain batch-specific COA
Related reading
- /research/thymosin-alpha-1 — compound profile with molecular and research data
- /category/healing-and-regeneration-research — broader immune/healing research category
- /guides/how-to-store-peptides — lyophilized peptide handling standards
- /peptide-calculator — reconstitution math
RUO disclaimer
For laboratory research use only. Not intended to diagnose, treat, cure, or prevent any disease. Not for human consumption outside approved research settings. All handling must comply with institutional policies and local regulations.